We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Drug Eluting Pantera Lux Catheter Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01081366
Recruitment Status : Completed
First Posted : March 5, 2010
Last Update Posted : January 22, 2016
Information provided by (Responsible Party):
Biotronik AG

March 4, 2010
March 5, 2010
January 22, 2016
April 2010
March 2012   (Final data collection date for primary outcome measure)
Major Adverse Cardiac Events (MACE) [ Time Frame: 6 M ]
Death, non-fatal MI, clinically driven target vessel revascularization (TVR)
Major Adverse Cardiac Events (MACE) [ Time Frame: 6 month ]
MACE: defined as death, non-fatal MI, clinically driven TVR
Complete list of historical versions of study NCT01081366 on ClinicalTrials.gov Archive Site
  • MACE [ Time Frame: 12 M ]
    Death, non-fatal MI, clinically driven TVR
  • All MACE [ Time Frame: 1, 6, and12 M ]
    Death, non-fatal MI, any revascularization
  • Clinically driven TVR [ Time Frame: 1, 6 and 12 M ]
  • Acute success [ Time Frame: Post procedure ]
    Clinical device success, clinical procedure success
Not Provided
Not Provided
Not Provided
Drug Eluting Pantera Lux Catheter Registry
Evaluation of the Safety Profile of the Pantera Lux Paclitaxel Releasing Balloon for Coronary Arteries in Daily Clinical Practice
All comers registry - Evaluation of the safety and efficacy of the Pantera Lux Paclitaxel releasing balloon for coronary arteries in daily clinical practice.

All patients are treated with the Pantera Lux Paclitaxel releasing balloon.

Clinical follow ups at 1, 6 and 12 months after coronary intervention.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
All comers registry. Patients treated with the Pantera Lux Paclitaxel releasing balloon catheter are enrolled consecutively to represent a typical set of patients at each site.
Coronary Artery Disease
Not Provided
Not Provided
Toelg R, Merkely B, Erglis A, Hoffman S, Bruno H, Kornowski R, Slagboom T, Naber C, Witzenbichler B, Graf K, Richardt G, Hehrlein C; DELUX investigators. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry. EuroIntervention. 2014 Sep;10(5):591-9. doi: 10.4244/EIJV10I5A102.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Signed Patient Informed Consent / Data Release Form
  • Patient eligible for percutaneous coronary intervention (PCI)
  • Patient is older than 18 years of age

Exclusion Criteria

  • Patient has a known allergy against appropriate anticoagulation / antiplatelet therapy
  • Patients with known allergy against paclitaxel or BTHC
  • Patients with a target lesion that was previously treated by brachytherapy
  • Pregnant woman or lactating woman
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Plan to Share IPD: No
Biotronik AG
Biotronik AG
Not Provided
Principal Investigator: Raph Toelg, MD Herz-Kreislauf-Zentrum, Segeberger Kliniken GmbH, Am Kurpark 1, 23795 Bad Segeberg, Germany
Biotronik AG
January 2016